home / stock / mrk / mrk news


MRK News and Press, Merck & Company Inc. From 06/20/24

Stock Information

Company Name: Merck & Company Inc.
Stock Symbol: MRK
Market: NYSE
Website: merck.com

Menu

MRK MRK Quote MRK Short MRK News MRK Articles MRK Message Board
Get MRK Alerts

News, Short Squeeze, Breakout and More Instantly...

MRK - Merck Is Partnering With America's Largest HBCU To Launch a Collaborative Biotechnology Learning Center

NORTHAMPTON, MA / ACCESSWIRE / June 20, 2024 / Building the workforce of tomorrow means investing in the students of today. That's why Merck has partnered with North Carolina Agricultural and Technical State University (N.C. A&T) - the largest historically Black college and university in the...

MRK - Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth

2024-06-20 10:00:19 ET Palm Beach, FL – June 20, 2024 –  The National Cancer Institute’s (NCI) funding of research projects is predicted to empower the Pancreatic Cancer Market to grow. A report from Future Market Insights said that: “… the increa...

MRK - Corvus Pharmaceuticals Is Ready To Take Flight

2024-06-20 06:53:11 ET Summary Corvus Pharmaceuticals has shown positive growth and maturity over the past six months, with new leadership and increased clinical trial activity. The company is expanding its label and IP developments, with trials in oncology and immunology, as well...

MRK - More Of The Same Isn't Good Enough For Roche

2024-06-18 16:03:19 ET Summary Roche continues to face challenges tied to lackluster revenue and profit outlook, questionable pipeline, and an underperforming diagnostics business. Roche spends aggressively on its pipeline (R&D and M&A) and is more successful than peers in...

MRK - Ideaya Biosciences Continues Its Pursuit Of 'Synthetic Lethality'

2024-06-18 11:23:25 ET Summary The stock of Ideaya Biosciences, Inc. has risen some 50% since we last visited this clinical stage development firm focused on "synthetic lethality." The company continues to advance its pipeline, has partnerships with several Big Pharma names, and h...

MRK - Merck gets FDA approval for Capvaxive pneumonia vaccine (update)

2024-06-18 09:01:00 ET More on Merck Merck & Co., Inc. (MRK) Goldman Sachs 45th Annual Global Healthcare Conference - (Transcript) Dividends And Innovation: Why Merck Is A Healthcare Stock Worth Buying Merck & Co., Inc. (MRK) Investor Event at ASCO 2024 (Tran...

MRK - Pfizer Stock: The Reversal Should Keep Going

2024-06-18 05:56:25 ET Summary Pfizer's stock initially showed signs of recovery, but then stagnated while the rest of the market continued to grow. However, I expect a recovery in the medium term. The Company's Q1 results showed strong performance in non-COVID products and cost-s...

MRK - Merck gets FDA approval for Capvaxive pneumonia vaccine

2024-06-17 17:51:22 ET More on Merck Merck & Co., Inc. (MRK) Goldman Sachs 45th Annual Global Healthcare Conference - (Transcript) Dividends And Innovation: Why Merck Is A Healthcare Stock Worth Buying Merck & Co., Inc. (MRK) Investor Event at ASCO 2024 (Tran...

MRK - U.S. FDA Approves CAPVAXIVE(TM) (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults

CAPVAXIVE (V116) is specifically designed for adults and covers serotypes responsible for approximately 84% of invasive pneumococcal disease in adults 50 years of age and older Across four Phase 3 studies, CAPVAXIVE demonstrated robust immune responses in both vaccine-naïve and vacci...

MRK - FDA Approves Merck's KEYTRUDA® (pembrolizumab) Plus Carboplatin and Paclitaxel as Treatment for Adult Patients With Primary Advanced or Recurrent Endometrial Carcinoma

KEYTRUDA is now the first and only anti-PD-1 therapy FDA-approved in combination with chemotherapy for adult patients with primary advanced or recurrent endometrial carcinoma regardless of mismatch repair status Approval marks the third FDA-approved indication for KEYTRUDA in endometrial ...

Previous 10 Next 10